cc-93538
mAbexperimental
Clinical trial activity
11 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
5
Phase 3
3
Phase 4
0
Earliest trial started Oct 1, 2009 (NCT00986037)
Timeline
Indications
Mechanism of action
- Interleukin-13INHIBITOR
Interleukin-13 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297864 ↗
Also known as
- abt-308
- rpc4046
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05638282 | Phase 1 | Dec 15, 2022 | Bristol-Myers Squibb |
| NCT05175352 | Phase 1 | Jun 7, 2022 | Bristol-Myers Squibb, Celgene |
| NCT05337345 | Phase 1 | May 2, 2022 | Bristol-Myers Squibb |
| NCT05214768 | Phase 3 | Mar 4, 2022 | Bristol-Myers Squibb, Celgene |
| NCT04991935 | Phase 3 | Sep 14, 2021 | Celgene |
| NCT04800315 | Phase 2 | May 14, 2021 | Celgene |
| NCT04753697 | Phase 3 | Feb 22, 2021 | Bristol-Myers Squibb, Celgene |
| NCT04373187 | Phase 1 | May 21, 2020 | Bristol-Myers Squibb, Celgene |
| NCT04096105 | Phase 1 | Oct 2, 2019 | Celgene |
| NCT02098473 | Phase 2 | Aug 31, 2014 | Celgene |
| NCT00986037 | Phase 1 | Oct 1, 2009 | Abbott |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Celgene | For profit | 8 | 8 | 3 | 2014 |
| Bristol-Myers Squibb | For profit | 6 | 2 | 2 | 2020 |
| Abbott | For profit | 1 | 1 | 1 | 2009 |
3 organizations
Page 1 / 1